Drug updated on 11/15/2023
|Capsule (oral; 40 mg)
| Ongoing and
- For the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
Product Monograph / Prescribing Information
|Exkivity (mobocertinib) Prescribing Information.
|Takeda Pharmaceuticals America Inc., Lexington, MA
Systematic Reviews / Meta-Analyses
|New therapies in non-small cell lung cancer with EGFR exon 20 insertion mutations.
|Journal of Oncology Pharmacy Practice
|Non-small cell lung cancer with EGFR exon 20 insertion mutation: a systematic literature review and meta-analysis of patient outcomes.
|Current Medical Research and Opinion